Related Experiment Video
Updated: Jul 17, 2026
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
09:34
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
Alemtuzumab in chronic lymphocytic leukemia
Danelle F James1, Thomas J Kipps
1University of California, San Diego, Division of Hematology & Oncology, UCSD Moores Cancer Center, Room #4311, 3855 Health Sciences Drive, La Jolla, CA 92093-0820, USA. dfjames@ucsd.edu
Future Oncology (London, England)
|February 7, 2007
Summary
Alemtuzumab effectively depletes lymphocytes in chronic lymphocytic leukemia (CLL) patients, showing promise for those resistant to other treatments. This review examines its efficacy and safety in CLL therapy.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Alemtuzumab targets CD52, a protein on lymphocytes.
- Chronic lymphocytic leukemia (CLL) is a B-cell malignancy.
- Current treatments have limitations, especially for refractory cases.
Purpose of the Study:
- To review clinical studies on alemtuzumab for CLL.
- To evaluate the efficacy and safety of alemtuzumab.
- To assess its use as monotherapy and in combination regimens.
Main Methods:
- Review of clinical trials and studies.
- Analysis of alemtuzumab's activity against CLL cells.
- Evaluation of safety profiles and adverse events.
Main Results:
- Alemtuzumab depletes lymphocytes in blood, spleen, and marrow.
- It shows efficacy in patients refractory to purine analogs like fludarabine.
- Effectiveness in resolving lymphadenopathy is limited.
Conclusions:
- Alemtuzumab is an approved monoclonal antibody for CLL treatment.
- It offers a therapeutic option for refractory CLL.
- Further evaluation of combination therapies is warranted.